Novogen’s latest experiment : utterly meaningless

Every time I read one of Novogen’s shitty press releases (ASX : NRT) about a new animal study, including today’s latest missive, I get really pissed off. My blood boils. Not just because these are tiny, mostly irrelevant, pre-clinical studies but because their quasi-science content simply betrays the underwhelming nature of the company. I don’t…

The new kid in town : AirXpanders

Just because a few of my recent posts have been a bit on the silly and sarcastic side, doesn’t mean that you should automatically think that I am going be all inappropriate in this post. Certainly, the female breast is a personal hobby of mine, and there is no denying that my juvenile sense of…

Novogen : Unacceptable Behaviour (Part II)

In this continuation of my prior rant about Novogen CEO Graham Kelly’s questionable interactions with shareholders on HotCopper, I want to specifically review each of the “questions” that appeared on HotCopper and perhaps share some perspectives that will help you to understand why I really despise this kind of informal chit-chat. I note that I have…

SIRFLOX : OS v PFS

In previous posts I have expressed my opinion that the spectacular pummeling of Sirtex followed by a fairly meteoric rise earlier this week was basically due to the fact that retail investors don’t understand the basics of clinical trials. I do think that Sirtex did a lousy job with communication (this week’s communication exercise was…

Nothing “Novo” about Novogen

I’ll keep this brief, because there isn’t much to say. My ire with this company blossomed last month when it announced that it had filed a patent. Yes, you heard me correctly. They didn’t receive a notice of allowance on a patent. They didn’t expand their intellectual property (IP) into an international territory of commercial…